Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents Insights From the Xience V Coronary Stent System Trials

被引:53
|
作者
Genereux, Philippe [1 ,2 ,3 ]
Rutledge, David R. [4 ]
Palmerini, Tullio [5 ]
Caixeta, Adriano [6 ,7 ]
Kedhi, Elvin [8 ]
Hermiller, James B. [9 ]
Wang, Jin [4 ]
Krucoff, Mitchell W. [10 ]
Jones-McMeans, Jennifer [4 ]
Sudhir, Krishnankutty [4 ]
Simonton, Charles A. [4 ]
Serruys, Patrick W. [11 ]
Stone, Gregg W. [1 ,2 ]
机构
[1] Columbia Univ, Med Ctr, New York, NY 10022 USA
[2] Cardiovasc Res Fdn, New York, NY USA
[3] Univ Montreal, Hop Sacre Coeur Montreal, Montreal, PQ, Canada
[4] Abbott Vasc, Santa Clara, CA USA
[5] Univ Bologna, Ist Cardiol, I-40126 Bologna, Italy
[6] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil
[7] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[8] Isala Klin, Zwolle, Netherlands
[9] St Vincent Heart Ctr Indiana, Indianapolis, IN USA
[10] Duke Univ, Med Ctr, Durham, NC USA
[11] Erasmus Univ Hosp, Rotterdam, Netherlands
关键词
drug-eluting stents; stents; thrombosis; LONG-TERM DURATION; MYOCARDIAL-INFARCTION; SPIRIT II; PREDICTORS; METAANALYSIS; DISCONTINUATION; IMPLANTATION; CLOPIDOGREL; EFFICACY; IMPACT;
D O I
10.1161/CIRCINTERVENTIONS.114.001362
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Whether premature dual antiplatelet therapy (DAPT) interruption is safe in patients receiving cobalt chromium everolimus-eluting stents remains controversial. We sought to examine the relationship between DAPT discontinuation and stent thrombosis (ST) after cobalt chromium everolimus-eluting stents. Methods and Results-Outcomes from 11 219 patients were pooled from 3 randomized trials and 4 registries with 2-year follow-up period after cobalt chromium everolimus-eluting stent implantation. Rates of definite/probable ST were analyzed according to DAPT discontinuation in the following time intervals: 0 to 30, 30 to 90, 90 to 180, 180 to 365, and 365 to 730 days. Eighty-five cases of ST (0.75%) occurred in 83 patients during 2 years, with 41 (48.2%) events occurring within 30 days. The 2-year ST rate in patients interrupting DAPT at any time was similar to that in patients never interrupting DAPT through 2 years (25/4067 [0.63%] versus 58/7152 [0.83%] respectively; P=0.27]. By propensity and DAPT usage-adjusted multivariable analysis, permanent DAPT discontinuation before 30 days was independently associated with the occurrence of ST (hazard ratio [95% confidence interval], 26.8 [8.4-85.4]; P<0.0001), whereas permanent DAPT discontinuation in any interval after 90 days was not associated with ST. Only 2 ST events occurred after DAPT discontinuation between 30 and 90 days (both between 30 and 60 days), and the association between permanent DAPT discontinuation and ST during this period is unclear (hazard ratio [95% confidence interval], 8.7 [2.0-37.3]; P=0.004 for adjusted analysis and 3.4 [0.8-13.8]; P=0.07 for the unadjusted analysis). Conclusions-In this large pooled experience, permanent DAPT discontinuation before 30 days after cobalt chromium everolimus-eluting stent implantation was strongly associated with ST, whereas DAPT discontinuation beyond 90 days appeared safe.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Stent Thrombosis and Dual Antiplatelet Interruption: Insights from the XIENCE V Everolimus-Eluting Coronary Stent System Trials
    Stone, Gregg W.
    Rutledge, David R.
    Sudhir, Krishnankutty
    Hermiller, James B.
    Serruys, Patrick W.
    Mao, Vivian W.
    Zhao, Weiying
    Yaqub, Manejeh
    Sood, Poornima
    Wang, Jin
    Cao, Sherry
    Zheng, Qing
    Jonnavithula, Lalitha K.
    Simonton, Charles A.
    Krucoff, Mitchell W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (20) : B23 - B24
  • [2] Xience V™ everolimus-eluting coronary stent
    Kukreja, Neville
    Onuma, Yoshinobu
    Serruys, Patrick W.
    EXPERT REVIEW OF MEDICAL DEVICES, 2009, 6 (03) : 219 - 229
  • [3] XIENCE V™ Everolimus-Eluting Coronary Stent System: A Preclinical Assessment
    Perkins, Laura E. L.
    Boeke-Purkis, Katrin H.
    Wang, Qing
    Stringer, Steven K.
    Coleman, Leslie A.
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2009, 22 : S28 - S40
  • [4] Current status of the Xience V (R) everolimus-eluting coronary stent system
    Claessen, Bimmer E.
    Caixeta, Adriano
    Henriques, Jose P. S.
    Piek, Jan J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (10) : 1363 - 1374
  • [5] XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent
    Beijk, Marcel A. M.
    Piek, Jon J.
    EXPERT REVIEW OF MEDICAL DEVICES, 2007, 4 (01) : 11 - 21
  • [6] Low Stent Thrombosis Risk with the XIENCE V® Everolimus-Eluting Coronary Stent: Evidence from Randomized and Single-Arm Clinical Trials
    Bezenek, Susan
    Hermiller, James
    Lansky, Alexandra
    Yaqub, Manejeh
    Hattori, Kyoko
    Cao, Sherry
    Sood, Poornima
    Sudhir, Krishnakutty
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2011, 24 (04) : 326 - 341
  • [7] The Real World Experience of the Everolimus-Eluting Coronary Stent System: Audit of Everolimus-Eluting Coronary Stents
    Aldous, Sally
    Smyth, David
    Blake, James
    McClean, Dougal
    Elliott, John
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2011, 24 (03) : 241 - 246
  • [8] Early definite stent thrombosis with everolimus-eluting stents
    Naito, Ryo
    Miyauchi, Katsumi
    Konishi, Hirokazu
    Tsuboi, Shuta
    Okazaki, Shinya
    Daida, Hiroyuki
    CLINICAL CASE REPORTS, 2015, 3 (10): : 854 - 857
  • [9] Clinical Outcomes in the Percutaneous Coronary Intervention of In-Stent Restenosis with the XIENCE V Everolimus-Eluting Stent
    Lee, Michael
    Yang, Tae
    Mahmud, Ehtisham
    Park, Kyung Woo
    Kim, Hyo-Soo
    Kim, Moo Hyun
    Dangas, George
    Hermiller, James, Jr.
    Krucoff, Mitchell
    Rutledge, David
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B140 - B140
  • [10] Evaluation of an Everolimus-Eluting Dedicated Bifurcation Stent in Comparison with Xience V™ Coronary Stent in a Porcine Coronary Model
    Sorop, Oana
    van Beusekom, Heleen M.
    Krabbendam, Ilona
    Boeke-Purkis, Katrin
    van der Giessen, Willem J.
    CIRCULATION, 2010, 122 (21)